(February 2023) The European Medicines Agency has started a review of medicines containing pseudoephedrine following concerns about the risk of posterior reversible encephalopathy syndrome (PRES) and reversible cerebral vasoconstriction syndrome (RCVS) from the use of over-the-counter decongestants containing pseudoephedrine.
- TRADE NAMES: Allegra-D (Sanofi-Aventis); Balminil; Benadryl (Pfizer); Bromfed (Muro); Deconsal; Eltor 120; Entex (Andrx); Maxiphed; Robidrine; Robitussin-CF (Wyeth); Sudafed (Pfizer); Trinalin (Schering)
- INDICATIONS: Nasal congestion
- CLASS: Adrenergic alpha-receptor agonist
- HALF-LIFE: 9–16 hours
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Bromocriptine, Fluoxetine, Fluvoxamine, Furazolidone, Iobenguane, MAO inhibitors, Paroxetine Hydrochloride, Phenelzine, Rasagiline, Sertraline, Tranylcypromine
Please login to view the rest of this drug profile.
Page last updated 08/02/2023
